Oncotarget

Research Papers:

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells

Hanyang Lin, Min Chen, Katharina Rothe, Matthew V. Lorenzi, Adrian Woolfson and Xiaoyan Jiang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:8637-8650. https://doi.org/10.18632/oncotarget.2353

Metrics: PDF 1358 views  |   HTML 1485 views  |   ?  


Abstract

Hanyang Lin1,2, Min Chen1, Katharina Rothe1,3, Matthew V. Lorenzi4, Adrian Woolfson4 and Xiaoyan Jiang1,2,3

1 Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada 

2 Department of Medicine, University of British Columbia, Vancouver, BC, Canada 

3 Department of Medical Genetics, University of British Columbia; Vancouver, BC, Canada 

4 Discovery Medicine Oncology, Bristol-Myers Squibb, Princeton, NJ, United States

Correspondence:

Xiaoyan Jiang, email:

Keywords: CML, BCR-ABL, leukemic stem cells, JAK2, TKI resistance, BMS-911543

Received: August 13, 2014 Accepted: August 15, 2014 Published: August 16, 2014

Abstract

Imatinib Mesylate (IM) and other tyrosine kinase inhibitor (TKI) therapies have had a major impact on the treatment of chronic myeloid leukemia (CML). However, TKI monotherapy is not curative, with relapse and persistence of leukemic stem cells (LSCs) remaining a challenge. We have recently identified an AHI-1-BCR-ABL-JAK2 protein complex that contributes to the transforming activity of BCR-ABL and IM-resistance in CML stem/progenitor cells. JAK2 thus emerges as an attractive target for improved therapies, but off-target effects of newly developed JAK2 inhibitors on normal hematopoietic cells remain a concern. We have examined the biological effects of a highly selective, orally bioavailable JAK2 inhibitor, BMS-911543, in combination with TKIs on CD34+ treatment-naïve IM-nonresponder cells. Combination therapy reduces JAK2/STAT5 and CRKL activities, induces apoptosis, inhibits proliferation and colony growth, and eliminates CML LSCs in vitro. Importantly, BMS-911543 selectively targets CML stem/progenitor cells while sparing healthy stem/progenitor cells. Oral BMS-911543 combined with the potent TKI dasatinib more effectively eliminates infiltrated leukemic cells in hematopoietic tissues than TKI monotherapy and enhances survival of leukemic mice. Dual targeting BCR-ABL and JAK2 activities in CML stem/progenitor cells may consequently lead to more effective disease eradication, especially in patients at high risk of TKI resistance and disease progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2353